These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21997232)

  • 21. A review of the treatment options for Huntington's disease.
    Bonelli RM; Hofmann P
    Expert Opin Pharmacother; 2004 Apr; 5(4):767-76. PubMed ID: 15102562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
    Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen function in the pathophysiology and treatment of male Huntington's disease patients.
    Ransome MI
    J Neuroendocrinol; 2012 Oct; 24(10):1275-83. PubMed ID: 22672384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease.
    Tedroff J; Waters S; Barker RA; Roos R; Squitieri F;
    J Huntingtons Dis; 2015; 4(2):131-40. PubMed ID: 26397894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD).
    Harris KL; Kuan WL; Mason SL; Barker RA
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):622-630. PubMed ID: 32229581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurogenesis in Huntington's disease: can studying adult neurogenesis lead to the development of new therapeutic strategies?
    Gil-Mohapel J; Simpson JM; Ghilan M; Christie BR
    Brain Res; 2011 Aug; 1406():84-105. PubMed ID: 21742312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of the treatment studies in Huntington's disease since 1990.
    Bonelli RM; Hofmann P
    Expert Opin Pharmacother; 2007 Feb; 8(2):141-53. PubMed ID: 17257085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unified Huntington's disease rating scale: clinical practice and a critical approach.
    Klempír J; Klempírova O; Spacková N; Zidovská J; Roth J
    Funct Neurol; 2006; 21(4):217-21. PubMed ID: 17367582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
    Hergert DC; Sanchez-Ramos J; Cimino CR
    J Clin Exp Neuropsychol; 2015; 37(9):981-7. PubMed ID: 26332177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice.
    Wood NI; Pallier PN; Wanderer J; Morton AJ
    Neurobiol Dis; 2007 Feb; 25(2):342-53. PubMed ID: 17095235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neuropsychological deterioration in Huntington's disease].
    Deus-Yela J; Pujol J; Espert R
    Rev Neurol; 1997 Aug; 25(144):1257-68. PubMed ID: 9340161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamotrigine in motor and mood symptoms of Huntington's disease.
    Shen YC
    World J Biol Psychiatry; 2008; 9(2):147-9. PubMed ID: 17853293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.
    Loi SM; Walterfang M; Velakoulis D; Looi JC
    Australas Psychiatry; 2018 Aug; 26(4):376-380. PubMed ID: 29687724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the pharmacological management of Huntington's disease.
    Frank S; Jankovic J
    Drugs; 2010 Mar; 70(5):561-71. PubMed ID: 20329804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic criteria for Huntington's disease based on natural history.
    Reilmann R; Leavitt BR; Ross CA
    Mov Disord; 2014 Sep; 29(11):1335-41. PubMed ID: 25164527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive impairment and behavioural difficulties in patients with Huntington's disease.
    Bourne C; Clayton C; Murch A; Grant J
    Nurs Stand; 2006 May 10-16; 20(35):41-4. PubMed ID: 16722121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs.
    Simpson JA; Lovecky D; Kogan J; Vetter LA; Yohrling GJ
    J Huntingtons Dis; 2016 Dec; 5(4):395-403. PubMed ID: 27983566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Huntington's disease: present treatments and future therapeutic modalities.
    Bonelli RM; Wenning GK; Kapfhammer HP
    Int Clin Psychopharmacol; 2004 Mar; 19(2):51-62. PubMed ID: 15076012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington's disease.
    Bouwens JA; Hubers AA; van Duijn E; Cobbaert CM; Roos RA; van der Mast RC; Giltay EJ
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1248-56. PubMed ID: 24957738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropsychiatry of Huntington's disease.
    Rosenblatt A
    Dialogues Clin Neurosci; 2007; 9(2):191-7. PubMed ID: 17726917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.